Experimental Hematology
Volume 36, Issue 11 , Pages 1449-1460.e1 , November 2008

AML1/ETO–induced survivin expression inhibits transcriptional regulation of myeloid differentiation

  • Mumtaz Yaseen Balkhi

      Affiliations

    • Dr. Balkhi is currently at the Department of Molecular Biology and Genetics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    • ,
  • Maximilian Christopeit
    • ,
  • Yong Chen
    • ,
  • Mulu Geletu
    • ,
  • Gerhard Behre

      Affiliations

    • Corresponding Author InformationOffprint requests to: Gerhard Behre, M.D., Bone Marrow Transplantation Unit, Internal Medicine IV, MLU University, Ernst–Grube–Str. 40, 06097 Halle, Germany

Received 26 September 2007 ,Revised 5 May 2008 ,Accepted 22 May 2008.

References 

  1. Bitter MA, Le Beau MM, Rowley JD, Larson RA, Golomb HM, Vardiman JW. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol. 1987;18:211–225
  2. Tighe JE, Calabi F. t(8;21) breakpoints are clustered between alternatively spliced exons of MTG8. Clin Sci (Lond). 1995;89:215–218
  3. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825–1831
  4. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811–820
  5. Racanicchi S, Maccherani C, Liberatore C, et al. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. Embo J. 2005;24:1232–1242
  6. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase–targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001;61:2–7
  7. Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. AML–1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood. 2000;96:3939–3947
  8. Chevallier N, Corcoran CM, Lennon C, et al. ETO protein of t(8;21) AML is a corepressor for Bcl–6 B–cell lymphoma oncoprotein. Blood. 2004;103:1454–1463
  9. Meyers S, Downing JR, Hiebert SW. Identification of AML–1 and the (8;21) translocation protein (AML–1/ETO) as sequence–specific DNA–binding proteins: the runt homology domain is required for DNA binding and protein–protein interactions. Mol Cell Biol. 1993;13:6336–6345
  10. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML–1B–dependent transcriptional activation. Mol Cell Biol. 1995;15:1974–1982
  11. Pabst T, Mueller BU, Harakawa N, et al. AML1/ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7:444–451
  12. Zhang DE, Hetherington CJ, Meyers S, et al. CCAAT enhancer–binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony–stimulating factor receptor promoter. Mol Cell Biol. 1996;16:1231–1240
  13. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1/ETO fusion gene. Nat Genet. 1997;15:303–306
  14. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA–A24–restricted cytotoxic T lymphocyte epitope of a tumor–associated protein, survivin. Clin Cancer Res. 2002;8:1731–1739
  15. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor–associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000;60:1815–1817
  16. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B, Tamm I. In vivo expression of survivin and its splice variant survivin–2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer. 2006;119:1291–1297
  17. Fukuda S, Pelus LM. Regulation of the inhibitor–of–apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091–2100
  18. Grignani F, Kinsella T, Mencarelli A, et al. High–efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 1998;58:14–19
  19. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344(Pt 2):305–311
  20. Behre G, Smith LT, Tenen DG. Use of a promoterless Renilla luciferase vector as an internal control plasmid for transient co–transfection assays of Ras–mediated transcription activation. Biotechniques. 1999;26:24–2628
  21. Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. Embo J. 1995;14:341–350
  22. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML–1–ETO, associates with C/EBP–alpha, inhibits C/EBP–alpha–dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol. 1998;18:322–333
  23. Erickson RL, Hemati N, Ross SE, MacDougald OA. p300 coactivates the adipogenic transcription factor CCAAT/enhancer–binding protein alpha. J Biol Chem. 2001;276:16348–16355
  24. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18:4301–4314
  25. Balkhi MY, Trivedi AK, Geletu M, et al. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post–translational protein modifications. Oncogene. 2006;25:7041–7058
  26. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. PU.1 (Spi–1) and C/EBP alpha regulate the granulocyte colony–stimulating factor receptor promoter in myeloid cells. Blood. 1996;88:1234–1247
  27. Legraverend C, Antonson P, Flodby P, Xanthopoulos KG. High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucleic Acids Res. 1993;21:1735–1742
  28. Timchenko N, Wilson DR, Taylor LR, et al. Autoregulation of the human C/EBP alpha gene by stimulation of upstream stimulatory factor binding. Mol Cell Biol. 1995;15:1192–1202
  29. Geletu M, Balkhi MY, Peer Zada AA, et al. Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up–regulation of Ubc9. Blood. 2007;110:3301–3309
  30. Kim J, Cantwell CA, Johnson PF, Pfarr CM, Williams SC. Transcriptional activity of CCAAT/enhancer–binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem. 2002;277:38037–38044
  31. Tonks A, Pearn L, Tonks AJ, et al. The AML1/ETO fusion gene promotes extensive self–renewal of human primary erythroid cells. Blood. 2003;101:624–632
  32. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A. 2005;102:11480–11485
  33. Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther. 2006;5:478–482
  34. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54
  35. Fukuda S, Pelus LM. Survivin a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087–1098

PII: S0301-472X(08)00230-0

doi: 10.1016/j.exphem.2008.05.008

Experimental Hematology
Volume 36, Issue 11 , Pages 1449-1460.e1 , November 2008

Article Tools

* Image Usage & Resolution